{
    "nct_id": "NCT05743036",
    "official_title": "A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination With Encorafenib and Cetuximab in Adults With Metastatic Colorectal Cancer",
    "inclusion_criteria": "* Histologically or cytologically confirmed metastatic Stage IV colorectal adenocarcinoma.\n* Documented evidence of a BRAF V600E mutation in tumor tissue or blood\n* Presence of measurable disease per RECIST version 1.1 guidelines.\n* Disease progression after 1 or 2 previous systemic regimens for metastatic disease\n* Adequate bone marrow function\n* Adequate hepatic and renal function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Documented clinical disease progression or radiographic disease progression during the screening period\n* Leptomeningeal disease.\n* Symptomatic brain metastasis.\n* Presence of acute or chronic pancreatitis.\n* Unable to swallow, retain, and absorb oral medications.\n* Clinically significant cardiovascular diseases\n* Evidence of active noninfectious pneumonitis.\n* Evidence of active and uncontrolled bacterial or viral infection, within 2 weeks prior to start of any of the study interventions\n* Participants with known positivity for HIV\n* Active hepatitis B or hepatitis C infection\n* Concurrent or previous other malignancy within 2 years of study entry\n* Has had an allogeneic tissue/solid organ transplant\n* Pregnant or females of childbearing potential who have a positive Î²-hCG laboratory test result within 14 days prior to enrollment or is breastfeeding",
    "miscellaneous_criteria": ""
}